Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

Por Healey, J. F., Parker, E. T., Lollar, P.
Publicado no J Thromb Haemost (2018)

Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

Por Hill-Eubanks, D C, Parker, C G, Lollar, P
Publicado em 1989

X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.

Por Brandstetter, H, Bauer, M, Huber, R, Lollar, P, Bode, W
Publicado em 1995

The Comparative Immunogenicity of Human and Porcine Factor VIII in Hemophilia A Mice

Por Healey, J. F., Parker, E. T., Barrow, R. T., Langley, T. J., Church, W. R., Lollar, P.
Publicado em 2009

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII

Por Grushin, K, Miller, J, Dalm, D, Parker, E T, Healey, J F, Lollar, P, Stoilova-McPhie, S
Publicado em 2014

Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Por Lollar, P, Parker, E T, Curtis, J E, Helgerson, S L, Hoyer, L W, Scott, M E, Scandella, D
Publicado em 1994

Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Por Mosesson, M W, Fass, D N, Lollar, P, DiOrio, J P, Parker, C G, Knutson, G J, Hainfeld, J F, Wall, J S
Publicado em 1990